The Mammary Ductal Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Mammary Ductal Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Mammary Ductal Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Mammary Ductal Carcinoma and features dormant and discontinued products.
GlobalData tracks seven drugs in development for Mammary Ductal Carcinoma by six companies/universities/institutes. The top development phase for Mammary Ductal Carcinoma is phase i with four drugs in that stage. The Mammary Ductal Carcinoma pipeline has six drugs in development by companies and one by universities/ institutes. Some of the companies in the Mammary Ductal Carcinoma pipeline products market are: Marker Therapeutics, F. Hoffmann-La Roche and Compugen.
The key targets in the Mammary Ductal Carcinoma pipeline products market include Receptor Tyrosine Protein Kinase ERBB 2, Protein Kinase C Beta Type, and Mucin 1.
The key mechanisms of action in the Mammary Ductal Carcinoma pipeline product include Estrogen Receptor Antagonist with one drug in Phase II. The Mammary Ductal Carcinoma pipeline products include six routes of administration with the top ROA being Intradermal and three key molecule types in the Mammary Ductal Carcinoma pipeline products market including Subunit Vaccine, and Monoclonal Antibody.
Mammary Ductal Carcinoma overview
Ductal carcinoma is a type of breast cancer that occurs in the milk ducts and moves into nearby tissues. There are two types of ductal carcinoma, invasive ductal carcinoma (IDC) and ductal carcinoma in situ (DCIS). If the abnormal cancer cells are seen inside the milk ducts, then it is DCIS. DCIS is also known as intraductal carcinoma or non-invasive ductal carcinoma. If the cancer occurs in the lining of milk ducts and invades the breast tissue beyond duct walls, then it is IDC. IDC is also known as infiltrating ductal carcinoma or ductal adenocarcinoma.
For a complete picture of Mammary Ductal Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
